<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608985</url>
  </required_header>
  <id_info>
    <org_study_id>AC-057A301</org_study_id>
    <nct_id>NCT00608985</nct_id>
  </id_info>
  <brief_title>Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia</brief_title>
  <acronym>RESTORA 1</acronym>
  <official_title>Multi-center, Double-blind, Randomized, Placebo-controlled, Active Reference, Parallel-group Polysomnography Study to Assess the Efficacy and Safety of a 16-day Oral Administration of ACT-078573 in Adult Subjects With Chronic Primary Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midnight Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Midnight Pharma, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A polysomnography study to evaluate the effect, safety and tolerability of oral
      administration of almorexant (ACT 078573) in adult subjects with primary insomnia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Day 1&amp;2 in Wake After Sleep Onset (WASO)</measure>
    <time_frame>From baseline to Day 1&amp;2</time_frame>
    <description>WASO was defined as the time spent in epochs scored as wake after onset of persistent sleep as determined by polysomnography (PSG) until lights on.
For WASO assessed at the study center, the mean of the 2 PSG nights at each of Visits 3 and 4 was used for Day 1&amp;2 and Day 15&amp;16</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Day 15&amp;16 in WASO</measure>
    <time_frame>From baseline to Day 15&amp;16</time_frame>
    <description>WASO was defined as the time spent in epochs scored as wake after onset of persistent sleep as determined by polysomnography (PSG) until lights on.
For WASO assessed at the study center, the mean of the 2 PSG nights at each of Visits 3 and 4 was used for Day 1&amp;2 and Day 15&amp;16</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 1&amp;2 in the Self-reported WASO (sWASO)</measure>
    <time_frame>From baseline to Week 1&amp;2</time_frame>
    <description>sWASO was the self-reported time spent awake after sleep onset as reported in the sleep diary. For sWASO assessed at home, the mean of all available data collected between Visits 3 and 4 (i.e., after the second morning of Visit 3 and before the first evening of Visit 4) was used for Week 1&amp;2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 1&amp;2 in Latency to Persistent Sleep (LPS)</measure>
    <time_frame>From baseline to Day 1&amp;2</time_frame>
    <description>LPS was defined as the time from the start of the PSG recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-wake (i.e., either sleep stage 1 (S1), sleep stage 2 (S2), slow-wave sleep (SWS), or rapid eye movement sleep(REM)) as determined by PSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 15&amp;16 in LPS</measure>
    <time_frame>From baseline to Day 15&amp;16</time_frame>
    <description>LPS was defined as the time from the start of the PSG recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-wake (i.e., either sleep stage 1 (S1), sleep stage 2 (S2), slow-wave sleep (SWS), or rapid eye movement sleep(REM)) as determined by PSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 1&amp;2 in Subjective Latency to Sleep Onset (sLSO)</measure>
    <time_frame>From baseline to Week 1&amp;2</time_frame>
    <description>sLSO was the self-reported time to fall asleep as reported in the sleep diary</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">709</enrollment>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>almorexant 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>almorexant 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>zolpidem 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>almorexant</intervention_name>
    <description>2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>almorexant</intervention_name>
    <description>1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem</intervention_name>
    <description>2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (18-64 years) with a diagnosis of primary insomnia.

        Exclusion Criteria:

          -  History of any sleep disorder, or any Diagnostic and Statistical Manual of Mental
             Disorders, 4th edition (DSM-IV) axis I disorder other than primary insomnia.

          -  Sleep apnea, or restless legs syndrome.

          -  Daytime napping of more than 1 hour per day.

          -  Important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2
             years prior to the screening visit.

          -  Unwillingness to refrain from drugs, over-the-counter or herbal medication having an
             effect on sleep or behavior.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Cluydts, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Cognitive and Biological Psychology, University of Brussels</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sleep Disorders Laboratory, Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Adult Sleep Center, Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Hospitpal, Private Bag</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Breathing and Sleep (IBAS)</name>
      <address>
        <city>Heidelburg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Woolcock Institute of Medical Research</name>
      <address>
        <city>Glebe</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Organisation</name>
      <address>
        <city>Kippa Ring</city>
        <zip>4021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Sleep Disorder Centre</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burnside Hospital Clinical Trials Centre</name>
      <address>
        <city>Toorak Gardens</city>
        <zip>5065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital, Department of Respiratory</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck, Department of Neurology</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rudolfinerhaus</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vienna - Department of Neurology</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Jolimont / Sleep Disorders Center, Hospital de Jolimont</name>
      <address>
        <city>Haine Saint Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Andre Vesale</name>
      <address>
        <city>Montigny le Tilleuil</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital St. Naum, Paediatr. Neurology</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT 'St. Marina'</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddeleni nasledne pece, Nemocnice Ceske Budejovice</name>
      <address>
        <city>Ceske Budejovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum pro poruchy spanku a bdeni, Neurologicka klinika</name>
      <address>
        <city>Katerinska</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava/Klinika detske neurologie SLEEP LABORATORY</name>
      <address>
        <city>Ostava-Poruba</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poradna pro porchy spanku a spankova, Laborator Unimeds s.r.o.</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somnocentrum Trutnov-spankova laborator, Oddeleni neurologie</name>
      <address>
        <city>Trutnov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scansleep Aps, Sovnlaegecentret</name>
      <address>
        <city>Arhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sovnlagecentret - Scan Sleep</name>
      <address>
        <city>Copenhagen</city>
        <zip>1364</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scan Sleep ApS, Sovnlaegecentret</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tutkimuskeskus Vitalmed</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unesta Research Center</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Turku, Sleep Research Unit</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Raymond Poincare</name>
      <address>
        <city>Garches</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie B, Hopital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre du Sommeil et de la Vigilance, Hopital Hotel Dieu de Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federation des Pathologies du Sommeil</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Sleep Research GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Benjamin Franklin, Klinik und Hochschulambulanz fur Psychiatrie und Psychotherapie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Hedwig-Krnkenhaus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy of the University Hospital of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH Gorlitz</name>
      <address>
        <city>Gorlitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interdisziplinäres Schlafmedizinisches Zentrum, Universitätsklinikum Giesen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH Potsdam</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik fur Psychiatre</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Schwerin GmbH</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOMNIBENE Institut fur Medizinische</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Disorder Centre, State Health Centre</name>
      <address>
        <city>Budapest</city>
        <zip>H-1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology , University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Neurology, University of Pecs</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Laboratory, Ilnd Hospital</name>
      <address>
        <city>Szeged</city>
        <zip>J-6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center, Unit for Sleep Research</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technion Sleep Medicine Center, Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Neurologico Casimiro Mondino, Centro Multidisciplinare di Medicina del Sonno, Servizio di Neurofisiopatologia</name>
      <address>
        <city>Bologna</city>
        <zip>IT-27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione San Raffaele del Monte Tabor, Centro per i Disturbi del Sonno</name>
      <address>
        <city>Milan</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro del Sonno, Dipartimento di Neuroscienze, Clinica Neuroligica, Università di Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>IT-56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Chorob Psychicznych i Zaburzen Nerwicowych ACK, Szpital AMG</name>
      <address>
        <city>Gdansk</city>
        <zip>890-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratorium Diagnostyka Snu, Pro-Medica</name>
      <address>
        <city>Krakow</city>
        <zip>30-002</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osrodek Diagnostyki i Leczenia Zaburzen Snu i Chorob Ukladu</name>
      <address>
        <city>Lodz</city>
        <zip>92-215</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Psychiatrii i Neurologii, Zaklad Neurofizjologii Klinicznej</name>
      <address>
        <city>Warsaw</city>
        <zip>02957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratorium Diagnostyka Snu, Pro-Medica</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMC Instytut Medyczny S.A</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. Neurologická klinika FNsP Bratislava Nemocnica Staré Mesto</name>
      <address>
        <city>Bratislava</city>
        <zip>81369</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologicka klinika, FN L. Pasteura Kosice</name>
      <address>
        <city>Kosice</city>
        <zip>04066</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BenMed Park Clinic</name>
      <address>
        <city>Benoni</city>
        <state>Johannesburg</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WITS Sleep Laboratory School of Physiology</name>
      <address>
        <city>Parktown</city>
        <state>Johannesburg</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gatesville Medical Centre</name>
      <address>
        <city>Gatesville</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Company of Mary Hospital</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset West Trial Centre</name>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau, Unidad Framacologia Clinica</name>
      <address>
        <city>Barcelona</city>
        <zip>E-08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones del Sueno</name>
      <address>
        <city>Madrid</city>
        <zip>28036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Dureta, Unidad de Psicologia</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe, Unidad de Neurofisiologi</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital MAZ, Unidad de Neurofisiologia y Sueno</name>
      <address>
        <city>Zaragoza</city>
        <zip>50015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carlanderska Sömnlaboratoriet</name>
      <address>
        <city>Goteborg</city>
        <zip>SE-144 35</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital, Neurology department Sleep Unit</name>
      <address>
        <city>Orebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aleris Fysiologlab</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric University Clinics (UPK) Basel, Sleep Medicine and Neurophysiology</name>
      <address>
        <city>Basel</city>
        <zip>CH-4025</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre pour l'Etude et le Traitement des Troubles du Sommeil Hopital Bell Idee</name>
      <address>
        <city>Chene-Bourg</city>
        <zip>CH-1225</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KSM Luzern Klinik fur Schlafmedizin, c/o Klinik St. Anna</name>
      <address>
        <city>Lucerne</city>
        <zip>CH-6006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich (USZ) Neurology Polyclinic, Center for Sleep Medicine</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KSM Zurzach Klinik fur Schlafmedizin</name>
      <address>
        <city>Zurzach</city>
        <zip>CH-5330</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical University n.a. O.O. BohomoletsChair of Diseases of Nervous System, City Clinical Hospital No.4, Neurological Departments I and II</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Edinburgh Sleep Centre</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The London Sleep Centre</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <results_first_submitted>December 21, 2012</results_first_submitted>
  <results_first_submitted_qc>February 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 7, 2013</results_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleeplessness</keyword>
  <keyword>orexin receptor antagonist</keyword>
  <keyword>almorexant</keyword>
  <keyword>insomnia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject, first visit was on 28 April 2008. The last subject, last visit (safety follow-up) was on 30 September 2009.</recruitment_details>
      <pre_assignment_details>There was a screening period of 14 to 28 days. Two randomized subjects (one in each almorexant (ACT-078573) dose group) did not receive double-blind study treatment. The 'Started population' was defined as those participants who were randomized and treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo
Placebo : 2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem</description>
        </group>
        <group group_id="P2">
          <title>Almorexant 100mg</title>
          <description>almorexant 100 mg
almorexant : 1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem</description>
        </group>
        <group group_id="P3">
          <title>Almorexant 200mg</title>
          <description>almorexant 200 mg
almorexant : 2 100 mg almorexant tablets, and 1 placebo matching over-encapsulated zolpidem</description>
        </group>
        <group group_id="P4">
          <title>Zolpidem 10mg</title>
          <description>zolpidem 10 mg
zolpidem : 2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="177">Randomized and started double-blind treatment</participants>
                <participants group_id="P2" count="186">Randomized and started double-blind treatment</participants>
                <participants group_id="P3" count="176">Randomized and started double-blind treatment</participants>
                <participants group_id="P4" count="168">Randomized and started double-blind treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Double-blind Treatment</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="171"/>
                <participants group_id="P4" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="161">Completed follow-up</participants>
                <participants group_id="P2" count="173">Completed follow-up</participants>
                <participants group_id="P3" count="170">Completed follow-up</participants>
                <participants group_id="P4" count="159">Completed follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative/Other</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo
Placebo : 2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem</description>
        </group>
        <group group_id="B2">
          <title>Almorexant 100mg</title>
          <description>almorexant 100 mg
almorexant : 1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem</description>
        </group>
        <group group_id="B3">
          <title>Almorexant 200mg</title>
          <description>almorexant 200 mg
almorexant : 2 100 mg almorexant tablets, and 1 placebo matching over-encapsulated zolpidem</description>
        </group>
        <group group_id="B4">
          <title>Zolpidem 10mg</title>
          <description>zolpidem 10 mg
zolpidem : 2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="177"/>
            <count group_id="B2" value="186"/>
            <count group_id="B3" value="176"/>
            <count group_id="B4" value="168"/>
            <count group_id="B5" value="707"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="176"/>
                    <measurement group_id="B4" value="168"/>
                    <measurement group_id="B5" value="707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.2" spread="11.69"/>
                    <measurement group_id="B2" value="44.1" spread="12.44"/>
                    <measurement group_id="B3" value="46.1" spread="11.83"/>
                    <measurement group_id="B4" value="45.1" spread="12.11"/>
                    <measurement group_id="B5" value="45.4" spread="12.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Day 1&amp;2 in Wake After Sleep Onset (WASO)</title>
        <description>WASO was defined as the time spent in epochs scored as wake after onset of persistent sleep as determined by polysomnography (PSG) until lights on.
For WASO assessed at the study center, the mean of the 2 PSG nights at each of Visits 3 and 4 was used for Day 1&amp;2 and Day 15&amp;16</description>
        <time_frame>From baseline to Day 1&amp;2</time_frame>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo : 2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O2">
            <title>Almorexant 100mg</title>
            <description>almorexant 100 mg
almorexant : 1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Almorexant 200mg</title>
            <description>almorexant 200 mg
almorexant : 2 100 mg almorexant tablets, and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O4">
            <title>Zolpidem 10mg</title>
            <description>zolpidem 10 mg
zolpidem : 2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 1&amp;2 in Wake After Sleep Onset (WASO)</title>
          <description>WASO was defined as the time spent in epochs scored as wake after onset of persistent sleep as determined by polysomnography (PSG) until lights on.
For WASO assessed at the study center, the mean of the 2 PSG nights at each of Visits 3 and 4 was used for Day 1&amp;2 and Day 15&amp;16</description>
          <population>All treated patients</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="186"/>
                <count group_id="O3" value="176"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="39.81" lower_limit="77.3" upper_limit="91.0"/>
                    <measurement group_id="O2" value="86.6" spread="39.17" lower_limit="80.0" upper_limit="92.3"/>
                    <measurement group_id="O3" value="92.3" spread="35.92" lower_limit="84.8" upper_limit="98.3"/>
                    <measurement group_id="O4" value="76.5" spread="36.95" lower_limit="69.3" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1&amp;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" spread="42.63" lower_limit="63.3" upper_limit="81.8"/>
                    <measurement group_id="O2" value="54.5" spread="37.65" lower_limit="47.3" upper_limit="61.0"/>
                    <measurement group_id="O3" value="46.4" spread="28.85" lower_limit="41.8" upper_limit="49.8"/>
                    <measurement group_id="O4" value="54.6" spread="36.05" lower_limit="49.0" upper_limit="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 1&amp;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="38.73" lower_limit="-19.3" upper_limit="-7.3"/>
                    <measurement group_id="O2" value="-29.0" spread="31.50" lower_limit="-33.0" upper_limit="-23.3"/>
                    <measurement group_id="O3" value="-40.4" spread="31.70" lower_limit="-47.5" upper_limit="-31.5"/>
                    <measurement group_id="O4" value="-17.9" spread="29.19" lower_limit="-25.3" upper_limit="-12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 1&amp;2 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-15.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.8</ci_lower_limit>
            <ci_upper_limit>-8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 1&amp;2 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-26.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.3</ci_lower_limit>
            <ci_upper_limit>-19.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 1&amp;2 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0376</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.5</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Day 15&amp;16 in WASO</title>
        <description>WASO was defined as the time spent in epochs scored as wake after onset of persistent sleep as determined by polysomnography (PSG) until lights on.
For WASO assessed at the study center, the mean of the 2 PSG nights at each of Visits 3 and 4 was used for Day 1&amp;2 and Day 15&amp;16</description>
        <time_frame>From baseline to Day 15&amp;16</time_frame>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo : 2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O2">
            <title>Almorexant 100mg</title>
            <description>almorexant 100 mg
almorexant : 1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Almorexant 200mg</title>
            <description>almorexant 200 mg
almorexant : 2 100 mg almorexant tablets, and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O4">
            <title>Zolpidem 10mg</title>
            <description>zolpidem 10 mg
zolpidem : 2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 15&amp;16 in WASO</title>
          <description>WASO was defined as the time spent in epochs scored as wake after onset of persistent sleep as determined by polysomnography (PSG) until lights on.
For WASO assessed at the study center, the mean of the 2 PSG nights at each of Visits 3 and 4 was used for Day 1&amp;2 and Day 15&amp;16</description>
          <population>All treated patients</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="186"/>
                <count group_id="O3" value="176"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="39.81" lower_limit="77.3" upper_limit="91.0"/>
                    <measurement group_id="O2" value="86.6" spread="39.17" lower_limit="80.0" upper_limit="92.3"/>
                    <measurement group_id="O3" value="92.3" spread="35.92" lower_limit="84.8" upper_limit="98.3"/>
                    <measurement group_id="O4" value="76.5" spread="36.95" lower_limit="69.3" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15&amp;16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="45.90" lower_limit="56.0" upper_limit="71.5"/>
                    <measurement group_id="O2" value="55.8" spread="35.07" lower_limit="50.5" upper_limit="59.0"/>
                    <measurement group_id="O3" value="51.8" spread="31.31" lower_limit="46.3" upper_limit="56.0"/>
                    <measurement group_id="O4" value="63.0" spread="42.31" lower_limit="56.5" upper_limit="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Day 15&amp;16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" spread="43.40" lower_limit="-22.0" upper_limit="-12.0"/>
                    <measurement group_id="O2" value="-29.6" spread="33.12" lower_limit="-33.5" upper_limit="-23.8"/>
                    <measurement group_id="O3" value="-36.3" spread="35.20" lower_limit="-43.8" upper_limit="-26.5"/>
                    <measurement group_id="O4" value="-15.1" spread="36.61" lower_limit="-19.0" upper_limit="-8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 15&amp;16 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-13.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.3</ci_lower_limit>
            <ci_upper_limit>-6.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 15&amp;16 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-19.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.3</ci_lower_limit>
            <ci_upper_limit>-12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 15&amp;16 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3358</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>11.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 1&amp;2 in the Self-reported WASO (sWASO)</title>
        <description>sWASO was the self-reported time spent awake after sleep onset as reported in the sleep diary. For sWASO assessed at home, the mean of all available data collected between Visits 3 and 4 (i.e., after the second morning of Visit 3 and before the first evening of Visit 4) was used for Week 1&amp;2</description>
        <time_frame>From baseline to Week 1&amp;2</time_frame>
        <population>All treated patients with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo : 2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O2">
            <title>Almorexant 100mg</title>
            <description>almorexant 100 mg
almorexant : 1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Almorexant 200mg</title>
            <description>almorexant 200 mg
almorexant : 2 100 mg almorexant tablets, and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O4">
            <title>Zolpidem 10mg</title>
            <description>zolpidem 10 mg
zolpidem : 2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 1&amp;2 in the Self-reported WASO (sWASO)</title>
          <description>sWASO was the self-reported time spent awake after sleep onset as reported in the sleep diary. For sWASO assessed at home, the mean of all available data collected between Visits 3 and 4 (i.e., after the second morning of Visit 3 and before the first evening of Visit 4) was used for Week 1&amp;2</description>
          <population>All treated patients with available data</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="173"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" spread="51.32" lower_limit="60.0" upper_limit="75.0"/>
                    <measurement group_id="O2" value="65.0" spread="60.49" lower_limit="59.5" upper_limit="72.0"/>
                    <measurement group_id="O3" value="69.0" spread="46.68" lower_limit="63.0" upper_limit="77.0"/>
                    <measurement group_id="O4" value="61.6" spread="48.29" lower_limit="55.0" upper_limit="70.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1&amp;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" spread="48.33" lower_limit="47.5" upper_limit="58.1"/>
                    <measurement group_id="O2" value="40.5" spread="50.87" lower_limit="34.5" upper_limit="48.3"/>
                    <measurement group_id="O3" value="42.9" spread="42.06" lower_limit="37.5" upper_limit="47.5"/>
                    <measurement group_id="O4" value="30.5" spread="42.26" lower_limit="25.9" upper_limit="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 1&amp;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.1" spread="31.84" lower_limit="-20.0" upper_limit="-9.2"/>
                    <measurement group_id="O2" value="-19.5" spread="36.93" lower_limit="-22.9" upper_limit="-12.7"/>
                    <measurement group_id="O3" value="-21.8" spread="32.5" lower_limit="-28.8" upper_limit="-17.5"/>
                    <measurement group_id="O4" value="-23.4" spread="33.22" lower_limit="-27.5" upper_limit="-19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 1&amp;2 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0186</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.3</ci_lower_limit>
            <ci_upper_limit>-1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 1&amp;2 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.4</ci_lower_limit>
            <ci_upper_limit>-4.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 1&amp;2 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-12.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.8</ci_lower_limit>
            <ci_upper_limit>-6.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 1&amp;2 in Latency to Persistent Sleep (LPS)</title>
        <description>LPS was defined as the time from the start of the PSG recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-wake (i.e., either sleep stage 1 (S1), sleep stage 2 (S2), slow-wave sleep (SWS), or rapid eye movement sleep(REM)) as determined by PSG</description>
        <time_frame>From baseline to Day 1&amp;2</time_frame>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo : 2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O2">
            <title>Almorexant 100mg</title>
            <description>almorexant 100 mg
almorexant : 1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Almorexant 200mg</title>
            <description>almorexant 200 mg
almorexant : 2 100 mg almorexant tablets, and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O4">
            <title>Zolpidem 10mg</title>
            <description>zolpidem 10 mg
zolpidem : 2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 1&amp;2 in Latency to Persistent Sleep (LPS)</title>
          <description>LPS was defined as the time from the start of the PSG recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-wake (i.e., either sleep stage 1 (S1), sleep stage 2 (S2), slow-wave sleep (SWS), or rapid eye movement sleep(REM)) as determined by PSG</description>
          <population>All treated patients</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="186"/>
                <count group_id="O3" value="176"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" spread="41.81" lower_limit="53.0" upper_limit="65.5"/>
                    <measurement group_id="O2" value="57.4" spread="37.03" lower_limit="52.0" upper_limit="63.3"/>
                    <measurement group_id="O3" value="54.1" spread="32.89" lower_limit="47.5" upper_limit="58.3"/>
                    <measurement group_id="O4" value="56.5" spread="34.60" lower_limit="52.3" upper_limit="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1&amp;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="34.64" lower_limit="32.3" upper_limit="44.0"/>
                    <measurement group_id="O2" value="28.8" spread="30.13" lower_limit="25.0" upper_limit="34.5"/>
                    <measurement group_id="O3" value="25.0" spread="21.97" lower_limit="22.3" upper_limit="28.3"/>
                    <measurement group_id="O4" value="22.5" spread="27.25" lower_limit="20.3" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 1&amp;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" spread="40.21" lower_limit="-19.5" upper_limit="-11.0"/>
                    <measurement group_id="O2" value="-24.8" spread="37.00" lower_limit="-29.8" upper_limit="-18.3"/>
                    <measurement group_id="O3" value="-22.5" spread="30.83" lower_limit="-27.5" upper_limit="-20.5"/>
                    <measurement group_id="O4" value="-29.4" spread="34.63" lower_limit="-35.8" upper_limit="-25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 1&amp;2 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0035</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-9.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.3</ci_lower_limit>
            <ci_upper_limit>-3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 1&amp;2 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-9.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.0</ci_lower_limit>
            <ci_upper_limit>-4.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 1&amp;2 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-16.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.0</ci_lower_limit>
            <ci_upper_limit>-9.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 15&amp;16 in LPS</title>
        <description>LPS was defined as the time from the start of the PSG recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-wake (i.e., either sleep stage 1 (S1), sleep stage 2 (S2), slow-wave sleep (SWS), or rapid eye movement sleep(REM)) as determined by PSG</description>
        <time_frame>From baseline to Day 15&amp;16</time_frame>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo : 2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O2">
            <title>Almorexant 100mg</title>
            <description>almorexant 100 mg
almorexant : 1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Almorexant 200mg</title>
            <description>almorexant 200 mg
almorexant : 2 100 mg almorexant tablets, and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O4">
            <title>Zolpidem 10mg</title>
            <description>zolpidem 10 mg
zolpidem : 2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 15&amp;16 in LPS</title>
          <description>LPS was defined as the time from the start of the PSG recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-wake (i.e., either sleep stage 1 (S1), sleep stage 2 (S2), slow-wave sleep (SWS), or rapid eye movement sleep(REM)) as determined by PSG</description>
          <population>All treated patients</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="186"/>
                <count group_id="O3" value="176"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" spread="41.81" lower_limit="53.0" upper_limit="65.5"/>
                    <measurement group_id="O2" value="57.4" spread="37.03" lower_limit="52.0" upper_limit="63.3"/>
                    <measurement group_id="O3" value="54.1" spread="32.89" lower_limit="47.5" upper_limit="58.3"/>
                    <measurement group_id="O4" value="56.5" spread="34.60" lower_limit="52.3" upper_limit="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15&amp;16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="35.33" lower_limit="26.0" upper_limit="37.8"/>
                    <measurement group_id="O2" value="29.3" spread="28.51" lower_limit="25.8" upper_limit="35.3"/>
                    <measurement group_id="O3" value="24.1" spread="22.48" lower_limit="21.5" upper_limit="28.0"/>
                    <measurement group_id="O4" value="24.6" spread="25.62" lower_limit="21.3" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 15&amp;16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.0" spread="46.10" lower_limit="-25.8" upper_limit="-16.3"/>
                    <measurement group_id="O2" value="-23.5" spread="35.90" lower_limit="-31.0" upper_limit="-20.0"/>
                    <measurement group_id="O3" value="-26.5" spread="31.10" lower_limit="-30.8" upper_limit="-22.8"/>
                    <measurement group_id="O4" value="-32.3" spread="34.19" lower_limit="-36.0" upper_limit="-26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 15&amp;16 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2237</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.0</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 15&amp;16 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0607</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-6.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.3</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 15&amp;16 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0017</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-10.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.3</ci_lower_limit>
            <ci_upper_limit>-4.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 1&amp;2 in Subjective Latency to Sleep Onset (sLSO)</title>
        <description>sLSO was the self-reported time to fall asleep as reported in the sleep diary</description>
        <time_frame>From baseline to Week 1&amp;2</time_frame>
        <population>All treated patients with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo : 2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O2">
            <title>Almorexant 100mg</title>
            <description>almorexant 100 mg
almorexant : 1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Almorexant 200mg</title>
            <description>almorexant 200 mg
almorexant : 2 100 mg almorexant tablets, and 1 placebo matching over-encapsulated zolpidem</description>
          </group>
          <group group_id="O4">
            <title>Zolpidem 10mg</title>
            <description>zolpidem 10 mg
zolpidem : 2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 1&amp;2 in Subjective Latency to Sleep Onset (sLSO)</title>
          <description>sLSO was the self-reported time to fall asleep as reported in the sleep diary</description>
          <population>All treated patients with available data</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="173"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" spread="33.68" lower_limit="52.0" upper_limit="64.5"/>
                    <measurement group_id="O2" value="55.0" spread="50.70" lower_limit="49.0" upper_limit="60.6"/>
                    <measurement group_id="O3" value="53.3" spread="27.93" lower_limit="50.5" upper_limit="58.4"/>
                    <measurement group_id="O4" value="50.5" spread="29.34" lower_limit="45.2" upper_limit="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1&amp;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="31.61" lower_limit="39.2" upper_limit="51.0"/>
                    <measurement group_id="O2" value="36.5" spread="40.64" lower_limit="32.9" upper_limit="41.7"/>
                    <measurement group_id="O3" value="34.5" spread="21.56" lower_limit="31.5" upper_limit="38.3"/>
                    <measurement group_id="O4" value="33.3" spread="21.50" lower_limit="31.1" upper_limit="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 1&amp;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="26.89" lower_limit="-15.1" upper_limit="-4.7"/>
                    <measurement group_id="O2" value="-16.2" spread="34.48" lower_limit="-19.3" upper_limit="-12.4"/>
                    <measurement group_id="O3" value="-16.2" spread="23.22" lower_limit="-19.9" upper_limit="-13.5"/>
                    <measurement group_id="O4" value="-17.2" spread="25.67" lower_limit="-19.9" upper_limit="-12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 1&amp;2 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1187</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 1&amp;2 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0017</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.5</ci_lower_limit>
            <ci_upper_limit>-2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 1&amp;2 compared with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0121</p_value>
            <method>Wilcoxon rank-sum</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.8</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events occurring after the start of study treatment and within 24 hours after the last dose of study treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo
Placebo : 2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem</description>
        </group>
        <group group_id="E2">
          <title>Almorexant 100mg</title>
          <description>almorexant 100 mg
almorexant : 1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem</description>
        </group>
        <group group_id="E3">
          <title>Almorexant 200mg</title>
          <description>almorexant 200 mg
almorexant : 2 100 mg almorexant tablets, and 1 placebo matching over-encapsulated zolpidem</description>
        </group>
        <group group_id="E4">
          <title>Zolpidem 10mg</title>
          <description>zolpidem 10 mg
zolpidem : 2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>MULTIPLE SCLEROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="72" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLEPHAROSPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>FOOD CRAVING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>BALANCE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSED MOOD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>NIGHTMARE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>MICTURITION URGENCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ouali Berkani/Clinical Trial Leader</name_or_title>
      <organization>Actelion Pharmaceuticals Ltd</organization>
      <phone>+41 61 565 5342</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

